SwePub
Sök i LIBRIS databas

  Extended search

L773:0002 8703 OR L773:1097 6744
 

Search: L773:0002 8703 OR L773:1097 6744 > (2020-2024) > Rationale and desig...

  • Erlinge, DavidLund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Molekylär kardiologi,Forskargrupper vid Lunds universitet,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Molecular Cardiology,Lund University Research Groups,Skåne University Hospital,Lund Univ, Skane Univ Hosp, Dept Cardiol, Clin Sci, SE-22185 Lund, Sweden.;Lund Univ, Skane Univ Hosp, Dept Cardiol, Clin Sci, Lund, Sweden. (author)

Rationale and design of INFINITY-SWEDEHEART : A registry-based randomized clinical trial comparing clinical outcomes of the sirolimus-eluting DynamX bioadaptor to the zotarolimus-eluting Resolute Onyx stent

  • Article/chapterEnglish2024

Publisher, publication year, extent ...

  • Elsevier,2024
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:oru-115425
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-115425URI
  • https://doi.org/10.1016/j.ahj.2024.07.016DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-228559URI
  • https://lup.lub.lu.se/record/66e47acd-218a-4e7d-8078-39e89e093c39URI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-537766URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:159354421URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • The study was funded by Elixir Medical.
  • BACKGROUND: Modern drug-eluting stents have seen significant improvements, yet still create a rigid cage within the coronary artery. There is a 2% to 4% annual incidence of target lesion failure (TLF) beyond 1 year, and half of the patients experience angina after 5 years. The DynamX bioadaptor is a sirolimus-eluting, thin (71 µm) cobalt-chromium platform with helical strands that unlock and separate after in vivo degradation of the bioresorbable polymer coating. This allows the vessel to return to normal physiological function and motion, along with compensatory adaptive remodeling, which may reduce the need for reintervention and alleviate angina following percutaneous coronary intervention (PCI).METHODS: The INFINITY-SWEDEHEART trial is a single-blind, registry-based randomized clinical trial (R-RCT) to evaluate the safety and effectiveness of the DynamX bioadaptor compared to the Resolute Onyx stent in the treatment of patients with ischemic heart disease with de novo native coronary artery lesions. The R-RCT framework allows for recruitment, randomization, and pragmatic data collection of baseline demographics, medications, and clinical outcomes using existing national clinical registries integrated with the trial database. The primary objective is to demonstrate noninferiority in terms of freedom from TLF (cardiovascular death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization) at 1 year. Powered secondary endpoints will be tested sequentially for superiority from 6 months to the end of follow-up (5 years) for the following: 1) TLF in all subjects, 2) target vessel failure in all subjects, and 3) TLF in subjects with acute coronary syndrome (ACS). Subsequent superiority testing will be performed at a time determined depending on the number of events, ensuring sufficient statistical power. Change in angina-related symptoms, function and quality of life will be assessed using the Seattle Angina Questionnaire-short version. Predefined sub-groups will be analyzed. In total, 2400 patients have been randomized at 20 sites in Sweden. Available baseline characteristic reveal relatively old age (68 years) and a large proportion of ACS patients including 25% STEMI and 37% NSTEMI patients.SUMMARY: The INFINITY-SWEDEHEART study is designed to evaluate the long-term safety and efficacy of the DynamX bioadaptor compared to the Resolute Onyx stent in a general PCI patient population.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Andersson, JonasUmeå University,Umeå universitet,Kardiologi,Umeå Univ, Dept Cardiol, Umeå, Sweden.(Swepub:umu)joan0102 (author)
  • Fröbert, Ole,1964-Örebro universitet,Institutionen för medicinska vetenskaper,Örebro University, Faculty of Health, Department of Cardiology, Örebro, Sweden; Department of Clinical Medicine, Faculty of Health, Aarhus University, Aarhus, Denmark,Aarhus University Hospital,Örebro Univ, Fac Hlth, Dept Cardiol, Örebro, Sweden.;Aarhus Univ, Fac Hlth, Dept Clin Med, Aarhus, Denmark.(Swepub:oru)oft (author)
  • Törnerud, MattiasKarolinska Institute,Karolinska Inst, Danderyd Hosp, Dept Cardiol, Stockholm, Sweden. (author)
  • Böhm, FelixUppsala universitet,Uppsala University,Uppsala kliniska forskningscentrum (UCR) (author)
  • Held, Claes,1956-Uppsala universitet,Uppsala University,Uppsala kliniska forskningscentrum (UCR),Kardiologi(Swepub:uu)clahe947 (author)
  • Elek, CandaceElixir Medical Corporation, CA, Milpitas, United States,Elixir Med Corp, Milpitas, CA USA. (author)
  • Sirhan, MotasimElixir Medical Corporation, CA, Milpitas, United States,Elixir Med Corp, Milpitas, CA USA. (author)
  • Oldgren, Jonas,1964-Uppsala universitet,Uppsala University,Kardiologi,Uppsala kliniska forskningscentrum (UCR)(Swepub:uu)jonaoldg (author)
  • James, Stefan,1964-Uppsala universitet,Uppsala University,Kardiologi,Uppsala kliniska forskningscentrum (UCR)(Swepub:uu)stjam367 (author)
  • KardiologiSektion II (creator_code:org_t)

Related titles

  • In:American Heart Journal: Elsevier277, s. 1-100002-87031097-6744

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view